Somatostatin Treatment of Psoriatic Arthritis
- 1 January 1988
- journal article
- Published by Wiley in International Journal of Dermatology
- Vol. 27 (1) , 56-58
- https://doi.org/10.1111/j.1365-4362.1988.tb02341.x
Abstract
Eighteen patients with psoriatic arthritis were treated for 48 hours with an infusion of somatostatin 250 fig/hr diluted in a 5% glucose solution. This therapy led to a reduction of joint pain and satisfactory clearing of cutaneous lesions immediately after treatment in eight patients, less marked results in four, and null in four. Two patients were dropped from the study because of negative side effects during administration of the drug. Fifteen days after treatment, the clearing of lesions and joint pain reduction were even more pronounced. The most encouraging results were obtained on erythrodermic and large plaque psoriasis and on the polyarticular involvement. We suggest that the use of this drug, whose side effects are discussed, should be limited to patients with polyarthritis showing severe cutaneous involvement.Keywords
This publication has 7 references indexed in Scilit:
- EPIDERMAL GROWTH FACTOR, SOMATOSTATIN, AND PSORIASISThe Lancet, 1983
- Somatostatin treatment of psoriasisArchives of Dermatological Research, 1982
- A potent cyclic hexapeptide analogue of somatostatinNature, 1981
- Psoriasis and human growth hormone: Aetiology and therapyArchives of Dermatological Research, 1981
- Treatment of psoriasis with SomatostatinArchives of Dermatological Research, 1981
- Psoriatic arthritisSeminars in Arthritis and Rheumatism, 1973